Navigation Links
Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Date:8/29/2007

Potential Earlier Identification of Toxicity, Efficacy for Pharmaceutical

Developers

REDWOOD CITY, Calif., Aug. 29 /PRNewswire/ -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing processes, today announced it has licensed important intellectual property from the California Institute of Technology for preparing and identifying drug metabolites (substances produced during drug metabolism). Codexis will incorporate this technology in development of new R&D productivity tools for use by the pharmaceutical industry.

This technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes by Frances Arnold, Ph.D., Dick and Barbara Dickinson Professor of Chemical Engineering and Biochemistry, Cal Tech. Dr. Arnold will join the Codexis Industrial Advisory Board.

"This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services Group. "Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July."

"Current metabolite identification and synthesis methods are based on classical chemistry methods, which can be slow and cumbersome," he added. "Combining Codexis' leading position as a developer of biocatalytic products and processes for the pharmaceutical industry with the techniques developed by Dr. Arnold will enable us to provide a powerful, efficient new tool set for rapid identification and synthesis of drug metabolites. These new tools could add considerable value in metabolite profiling as well as lead diversification in drug discovery."

Drug metabolites are produced by the body during the break-down (metabolism) of drugs. Primary metabolites are largely formed in the liver by human P450 enzymes to aid in elimination of a drug from the body. In some cases, metabolites can be toxic, while for other drugs, "active" metabolites have shown improved efficacy and lower toxicity than the administered drug substance. The US Food and Drug Administration now recommends metabolic characterization for all new investigational human therapeutics.

Codexis, Inc. is a leading developer of clean biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. Codexis' proprietary directed evolution technologies enable novel solutions for efficient, cost-effective and environmentally friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the company was recognized by the U.S. EPA with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information please visit http://www.codexis.com

Contact: Justin Jackson, jjackson@burnsmc.com of Burns McClellan, 212-213-0006, or Lyn Christenson, Codexis, lyn.christenson@codexis.com, 650-298-5368.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
7. Detection of nitrofurane metabolites in food with HPLC/MS/MS
8. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
9. High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS
10. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
11. Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):